Search Close Search
Search Close Search
Page Menu

Student External Award for Research Training Details

  • Title graphic with the text “Maria Predtechenskaya,” “Keeler Research Group,” and “Funding provided by American Society of Gene & Cell Therapy” on a blue background.

    Long-term Immune Responses to Lipid Nanoparticle Therapy

    Dr. Predtechenskaya is a postdoc investigating immune responses to gene therapies, such as AAV, lipid nanoparticles, and chimeric antigen receptor regulatory T-cells in the lab of Dr. Allison Keeler at UMass Chan Medical School. She completed her PhD in Microbiology and Immunology at Montana State University, where she discovered the protective, anti-bacterial role of lung surfactant and proposed using commercially available surfactant as a therapeutic. After her PhD project took a translational turn, Dr. Predtechenskaya wanted to pivot into therapeutic space where she works now. Her projects focus on how to avoid the immune system to boost and prolong gene editing as well as minimizing inflammation in neurological disorders.

    Read more
  • Title graphic with the text “Alejandro Félix Mejía,” “Khvorova Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Engineering bacterial group I introns for efficient production of safe and durable nucleoside-modified circular mRNA therapeutics

    Synthetic messenger RNAs (mRNAs) represent a new class of biopharmaceuticals with broad clinical utility. Circular mRNAs are more stable than linear mRNAs because they resist degradation by cellular exonucleases, but current circularization methods are often incompatible with nucleoside modifications such as pseudouridine (Ψ) and N1-methylpseudouridine (m1Ψ). This project seeks to determine how uridine modifications affect the structure and function of bacterial group I introns and to develop engineered intron variants capable of efficiently circularizing modified RNAs. The research aims to create safe and durable circular mRNA therapeutics, expanding the potential applications of RNA medicines beyond vaccines.

    Read more
  • Title graphic with the text “Nicolai Hathiramani,” “Spinelli Research Group,” and “Funding provided by American Heart Association” on a blue background.

    Uncovering the physiological relevance of reprogramming the ETC in myocardial ischemia

    This project investigates the physiological relevance of reprogramming the mitochondrial electron transport chain (ETC) during myocardial ischemia. The research aims to better understand how alterations in mitochondrial energy metabolism influence cardiac function under ischemic conditions and may identify mechanisms with therapeutic relevance for cardiovascular disease.

    Read more
  • Title graphic with the text “Rebekka Anderson,” “Alkema Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Determine the role of a monocarboxylate transporter in metabolism and intestinal motility

    Monocarboxylate transporters (MCTs) mediate the transport of key metabolic intermediates, including lactate, urate, and pyruvate, across cellular membranes. Although MCTs play important roles in metabolic homeostasis and have been implicated in cancer, cardiovascular disease, and neurodegeneration, many members of this transporter family remain poorly understood. Using the model organism Caenorhabditis elegans, this project investigates the function of slcf-1, a transporter homologous to human MCT9. A genetic screen identified a mutation in slcf-1 that causes defects in intestinal motility and alters intestinal calcium waves that regulate the defecation motor program. These findings suggest a previously unrecognized link between monocarboxylate transporters, metabolism, calcium homeostasis, and gut function. The project aims to: Determine how slcf-1 mutations alter intestinal calcium wave dynamics and characterize the localization and tissue-specific functions of SLCF-1. Identify the substrates transported by SLCF-1 and determine how transporter activity is regulated. Define the metabolic consequences of slcf-1 loss by examining mitochondrial function, cellular stress responses, and broader metabolic pathway changes. Because human MCT9 has been associated with hyperuricemia, cardiovascular disease, gout, and renal cell carcinoma, these studies will provide insight into how conserved monocarboxylate transporters link metabolism, calcium signaling, and intestinal motility, contributing to a broader understanding of their roles in human health and disease.

    Read more
  • Title graphic with the text “Arshia Kaur,” “Watson Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Exploring autophagy as a cellular response to fusion oncogene-induced stress

    Rare cancers account for approximately 20% of all cancer diagnoses, yet they have significantly fewer research resources, experimental models, and patient samples available compared to more common cancers. Many rare cancers are driven by recurrent chromosomal translocations that generate unique fusion oncogenes, but the biological functions of most fusion oncogenes remain poorly understood. To address this challenge, researchers developed the Rare Cancer Fusion Oncogene Library (RCFOL), a collection of more than 2,500 barcoded fusion oncogene constructs designed for large-scale functional studies. Using the RCFOL, preliminary studies identified fusion oncogenes from soft-tissue sarcomas that caused fitness defects in human mammary epithelial cells. One fusion oncogene, EWSR1::CREB1, induced autophagy-dependent cell death in response to oncogenic stress and was associated with activation of innate immune signaling pathways. In contrast, fibroblast cells tolerated expression of the same fusion oncogene without adverse effects, suggesting that some cell types are "permissive" while others are "non-permissive" to fusion oncogene expression. The central hypothesis of this project is that induction of autophagy-dependent cell death through innate immune signaling represents a conserved defense mechanism against fusion oncogene expression in non-permissive cell types. Specific Aims Aim 1: Determine the role of IL-6 signaling and differential fusion-binding patterns in the selective induction of autophagy-dependent cell death in EWSR1::CREB1-expressing cells. Studies will evaluate autophagic activity, localization of autophagy regulators, cell death mechanisms, and genomic binding patterns using molecular and imaging approaches. Aim 2: Investigate whether autophagy is a conserved tumor-suppressive response to oncogenic stress by conducting multiplexed proliferation screens of fusion oncogenes and measuring autophagic flux, cell death, and cytokine secretion. This work will provide new insight into how cells respond to fusion oncogene-induced stress and may reveal novel tumor-suppressive mechanisms operative in rare cancers. The findings could identify new therapeutic opportunities for cancers driven by fusion oncogenes.

    Read more
  • Title graphic with the text “Chengzhi Yu,” “Fu Research Group,” and “Funding provided by Cancer Research Institute” on a blue background.

    Decoding the RHIM Signalosome in the ZBP1-RIPK3 Pathway for Antitumor Immunity

    Cancer cells often evade detection by the immune system, limiting the effectiveness of cancer immunotherapies. One important but incompletely understood immune pathway centers on the protein ZBP1, which functions as an intracellular alarm sensor. When activated, ZBP1 can trigger inflammatory signaling and a specialized form of programmed cell death called necroptosis. These responses can help expose tumors to immune surveillance and promote anti-tumor immunity. However, the molecular mechanisms that activate and regulate this pathway remain poorly understood. Chengzhi Yu's research seeks to determine how ZBP1 and its signaling partner RIPK3 assemble into larger signaling complexes known as RHIM signalosomes. Using structural biology, high-resolution imaging, and biochemical approaches, the project will define the molecular mechanisms that govern activation of the ZBP1-RIPK3 pathway and inflammatory cell death. The research will also investigate how viral proteins, including proteins encoded by herpesviruses, interfere with RHIM signalosome formation and suppress immune responses. Understanding these viral evasion strategies may provide important insight into how immune signaling pathways are naturally regulated. By revealing the molecular "assembly instructions" that control ZBP1 signaling, this work aims to identify new approaches for enhancing anti-tumor immunity, overcoming immune suppression, and improving responses to cancer immunotherapies such as immune checkpoint blockade.

    Read more
  • Title graphic with the text “William Cruz,” “Korostelev Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Understanding the Activation Mechanism of the Nutrition Sensor GCN2

    The protein kinase GCN2 is a regulator of translation during amino acid starvation and plays a critical role in cellular proliferation. Dysregulated GCN2 activity contributes to severe human diseases, including pulmonary arterial hypertension and pulmonary veno-occlusive disease, as well as cardiac diseases. Despite decades of study, the mechanism by which human GCN2 is activated in cells and how its full-length structure supports this regulation remains elusive. Existing models propose activation through either uncharged tRNA accumulation or stalled ribosome, but prior biochemical studies relied largely on purified components, leaving out essential ribosome-associated factors such as GCN1/GCN20, which are necessary for a greater picture of activation. Moreover, no complete structure of human GCN2 has been determined, leaving key regulatory linker regions poorly understood. This fellowship project seeks to define the molecular mechanism of human GCN2 activation and elucidate how linker regions contribute to GCN2 regulation. Aim 1 will determine the structure of activated full-length GCN2 in nutritionally starved lysate using cryo-electron microscopy, enabling visualization of GCN2 in the context of ribosomes, tRNA, and endogenous accessory proteins. Aim 2 will evaluate the regulatory roles of GCN2 linker regions using a HEK293-based system expressing targeted mutants, assessing effects on kinase activation, ribosome binding, and dimerization through biochemical and cell-based assays. Together, these aims will produce the first structural model of activated full-length human GCN2 and define how linker regions modulate GCN2’s function, providing insight relevant to diseases driven by aberrant GCN2. The proposed research is integrated with a comprehensive training plan designed to develop the fellow into an independent structural biologist. The fellowship includes structured technical training in cryo-EM grid preparation, data collection, and advanced image processing; biochemical and cell-based assays; and rigorous design of structural biology and computational experiments. The plan will also significantly enhance the fellow’s research knowledge of lysate-based structural methods, kinase signaling assays, and computational reconstruction of macromolecules. Completion of this fellowship will yield mechanistic insights into GCN2 activation while providing broad and deep scientific training that positions the fellow for a successful research career focused on mechanisms of translational control.

    Read more
  • Title graphic with the text “Matthew Wong,” “Munro and Schiffer Research Groups,” and “Funding provided by National Institutes of Health” on a blue background.

    Conformational Dynamics in HIV-1 Gag during Viral Maturation

    Human immunodeficiency virus type 1 (HIV-1) remains a major global health challenge. While viral maturation has long been a promising target for inhibitor development, the emergence ofresistance to protease inhibitors continues to limit their effectiveness. As such, the Group-Specific Antigen (Gag) polyprotein presents an alternative avenue for therapeutic intervention, marked by the recent development of novel antiretrovirals such as bevirimat and lenacapavir, which target the immature Gag and mature capsid (CA). Gag encodes the core structural proteins that form the viral particle and undergoes cleavage by the viral protease during maturation. Among the domains in Gag, CA-SP1 cleavage is the key determinant for CA maturation, a process marked by CA undergoing drastic conformational changes. In Aim 1, I will elucidate how the stability of SP1 helices evolves during proteolysis. SP1 helices are arranged mostly in relatively stable six-helix bundles in the immature lattice but are bound to the protease extended and unfolded. It remains unclear how SP1 loses its secondary structure as it binds to the protease. I hypothesize that the initial cleavage of a single SP1 helix destabilizes the six-helix bundle, promoting the unfolding of neighboring helices and allowing for easier access to the protease. Using MD simulations, I will elucidate and compare the unfolding timescale and mechanisms of SP1 helices within fully intact and partially cleaved hexamers. I predict that SP1 helices in the cleaved hexamers will unfold more readily, whereas the intact hexamer will remain predominantly stable. These simulations will provide mechanistic insights into how SP1 proteolysis propagates structural changes through the hexamer and contributes to how the crucial last step of Gag proteolytic processing occurs. The expertise from the Schiffer lab provides me with the necessary training needed to perform robust structural modeling and molecular dynamics simulations. In Aim 2, I will investigate how SP1 cleavage mediates CA conformational changes that facilitate maturation. The destabilization ofthe six-helix bundle has been identified as the key structural switch for CA maturation. Using smFRET, I will visualize the conformational changes of single CA molecules within oligomeric assemblies. I predict that destabilization of the six-helix bundle following CA-SP1 cleavage induces conformational changes to the CA domain that are relevant for virion maturation. These findings will provide mechanistic insights into the allosteric communication between the CA-SP1 cleavage site and CA domains, revealing how initial cleavage events prime the hexamer for further structural transitions. The Munro lab has a proven track record and expertise in visualizing dynamic events in virions using single molecule fluorescence- based techniques. This study will significantly advance our understanding of the molecular mechanisms underlying HIV-1 maturation, potentially shedding light on the maturation processes of other retroviruses.

    Read more
  • Person standing indoors near a staircase and glass railing, next to text identifying Rebecca Panwala of the Sontheimer and Xue Research Group, with funding provided by the National Institutes of Health.

    High throughput screening to generate and investigate cancer driver mutations in hepatocellular carcinoma.

    Cancer remains a leading cause of death in the United States and globally. Understanding the genetic mutations that drive cancer can help inform diagnosis, prognosis, and treatment options. Cancer driver mutations are thought to cause tumor formation and malignancy by leading to abnormal and uncontrolled cellular growth. To date, thousands of cancer driver mutations have been identified in hundreds of genes. Experimental models that precisely install cancer driver mutations are essential for investigating the mechanisms that underlie cancer. CRISPR-based prime editing offers a comprehensive way to generate a diverse array of cancer driver mutations, including substitutions, insertions, deletions, or combinations. In prime editing, a prime editing guide RNA (pegRNA) guides mutant Cas9 to nick one strand of the genome target site and serves as a template for reverse transcriptase (fused to Cas9) to copy new information into the genome. However, designing and validating effective pegRNAs is expensive and time-consuming. Preliminary experiments using a high-throughput screening approach based on Next Generation Sequencing identified pegRNAs that guide efficient editing. This screen enabled simultaneous testing of thousands of pegRNA designs for their ability to edit frequent mutations in hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer. This project aims to use these pegRNA constructs to further characterize HCC mutations and to generate a mouse model of HCC. Aim 1will characterize the cellular and molecular effects of HCC driver mutations. Utilizing a library of the highest efficacy pegRNAs from the preliminary screen, a secondary screen will be performed to identify which mutations confer a growth advantage in transformed primary human hepatocytes. Cellular fitness results from this screen will be validated using a competition assay. Cellular and molecular phenotypes of mutations that promote fitness will then be characterized. Colony formation assays will determine the ability of cells with cancer driver mutations to expand into a clonal population. RNA sequencing will reveal transcriptional profiles associated with the cancer mutation. Aim 2will model HCC driver mutations in vivo. Prime editing will be used to install cancer mutations in transformed primary human hepatocytes, and cells will be orthotopically implanted into the livers of immune-deficient mice via intrahepatic injection. After a period of growth, tumor formation and the histopathology and gene expression signatures of the tumors will be analyzed. This study will be piloted with pegRNAs (identified from the preliminary screen)that generated an activating mutation in the conserved -catenin gene CTNNB1.An activating mutation inCTNNB1combined with co-expression of the MYC oncogene was sufficient to drive tumor progression in mice. In vivo models of cancer driver mutations will be used to assess how tumors respond to treatment with first-line therapies for HCC. If successful, this project will generate a system to further characterize HCC driver mutations at the cellular level and in tumors, informing potential treatment approaches based on the genetic profiles of cancer.

    Read more
  • Person standing in front of a staircase, next to text identifying Emily Norman of the Francis Research Group, with funding provided by the National Institutes of Health.

    Cognitive decline is a major hallmark of aging

    Cognitive decline is a major hallmark of aging. Synapse loss and structural alterations are believed to be major contributing factors to normal age-related cognitive decline and are exacerbated in cases of neurodegenerative diseases such as Alzheimer's disease. The goal of this project is to identify conserved mechanisms responsible for synapse maintenance in aging animals. The short lifespan, invariant neuronal circuitry, and genetic tools available in the invertebrate Caenorhabditis elegans offer strong advantages for studies of synapse maintenance. While prior studies have largely focused on gross neuron morphological changes during aging, my work is focused on understanding age-related synapse changes. The Francis lab previously demonstrated that C. elegans GABAergic DD motor neurons have dendritic spines which share many characteristics with mammalian dendritic spines. My work focuses on understanding the mechanisms which regulate age-related synapse decline. My preliminary studies suggest that dendritic spine number is reduced in aging animals. My proposed work will define how aging impacts synapse structure and define the mechanisms required for synapse maintenance during aging (Aim 1). In Aim 2, I will identify potential postsynaptic targets crucial for synapse maintenance using proximity labeling and subsequent proteomic analyses. My proposed work will advance our understanding of the mechanisms regulating synapse maintenance in aging animals and potentially identify new gene targets for therapeutic intervention. Importantly, the proposed studies will also provide significant opportunities for new technical and professional training for the applicant.

    Read more
1-10  of  100  items
of 10
Getting Results…
  • Title graphic with the text “Maria Predtechenskaya,” “Keeler Research Group,” and “Funding provided by American Society of Gene & Cell Therapy” on a blue background.

    Long-term Immune Responses to Lipid Nanoparticle Therapy

    Dr. Predtechenskaya is a postdoc investigating immune responses to gene therapies, such as AAV, lipid nanoparticles, and chimeric antigen receptor regulatory T-cells in the lab of Dr. Allison Keeler at UMass Chan Medical School. She completed her PhD in Microbiology and Immunology at Montana State University, where she discovered the protective, anti-bacterial role of lung surfactant and proposed using commercially available surfactant as a therapeutic. After her PhD project took a translational turn, Dr. Predtechenskaya wanted to pivot into therapeutic space where she works now. Her projects focus on how to avoid the immune system to boost and prolong gene editing as well as minimizing inflammation in neurological disorders.

    Read more
  • Title graphic with the text “Alejandro Félix Mejía,” “Khvorova Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Engineering bacterial group I introns for efficient production of safe and durable nucleoside-modified circular mRNA therapeutics

    Synthetic messenger RNAs (mRNAs) represent a new class of biopharmaceuticals with broad clinical utility. Circular mRNAs are more stable than linear mRNAs because they resist degradation by cellular exonucleases, but current circularization methods are often incompatible with nucleoside modifications such as pseudouridine (Ψ) and N1-methylpseudouridine (m1Ψ). This project seeks to determine how uridine modifications affect the structure and function of bacterial group I introns and to develop engineered intron variants capable of efficiently circularizing modified RNAs. The research aims to create safe and durable circular mRNA therapeutics, expanding the potential applications of RNA medicines beyond vaccines.

    Read more
  • Title graphic with the text “Nicolai Hathiramani,” “Spinelli Research Group,” and “Funding provided by American Heart Association” on a blue background.

    Uncovering the physiological relevance of reprogramming the ETC in myocardial ischemia

    This project investigates the physiological relevance of reprogramming the mitochondrial electron transport chain (ETC) during myocardial ischemia. The research aims to better understand how alterations in mitochondrial energy metabolism influence cardiac function under ischemic conditions and may identify mechanisms with therapeutic relevance for cardiovascular disease.

    Read more
  • Title graphic with the text “Rebekka Anderson,” “Alkema Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Determine the role of a monocarboxylate transporter in metabolism and intestinal motility

    Monocarboxylate transporters (MCTs) mediate the transport of key metabolic intermediates, including lactate, urate, and pyruvate, across cellular membranes. Although MCTs play important roles in metabolic homeostasis and have been implicated in cancer, cardiovascular disease, and neurodegeneration, many members of this transporter family remain poorly understood. Using the model organism Caenorhabditis elegans, this project investigates the function of slcf-1, a transporter homologous to human MCT9. A genetic screen identified a mutation in slcf-1 that causes defects in intestinal motility and alters intestinal calcium waves that regulate the defecation motor program. These findings suggest a previously unrecognized link between monocarboxylate transporters, metabolism, calcium homeostasis, and gut function. The project aims to: Determine how slcf-1 mutations alter intestinal calcium wave dynamics and characterize the localization and tissue-specific functions of SLCF-1. Identify the substrates transported by SLCF-1 and determine how transporter activity is regulated. Define the metabolic consequences of slcf-1 loss by examining mitochondrial function, cellular stress responses, and broader metabolic pathway changes. Because human MCT9 has been associated with hyperuricemia, cardiovascular disease, gout, and renal cell carcinoma, these studies will provide insight into how conserved monocarboxylate transporters link metabolism, calcium signaling, and intestinal motility, contributing to a broader understanding of their roles in human health and disease.

    Read more
  • Title graphic with the text “Arshia Kaur,” “Watson Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Exploring autophagy as a cellular response to fusion oncogene-induced stress

    Rare cancers account for approximately 20% of all cancer diagnoses, yet they have significantly fewer research resources, experimental models, and patient samples available compared to more common cancers. Many rare cancers are driven by recurrent chromosomal translocations that generate unique fusion oncogenes, but the biological functions of most fusion oncogenes remain poorly understood. To address this challenge, researchers developed the Rare Cancer Fusion Oncogene Library (RCFOL), a collection of more than 2,500 barcoded fusion oncogene constructs designed for large-scale functional studies. Using the RCFOL, preliminary studies identified fusion oncogenes from soft-tissue sarcomas that caused fitness defects in human mammary epithelial cells. One fusion oncogene, EWSR1::CREB1, induced autophagy-dependent cell death in response to oncogenic stress and was associated with activation of innate immune signaling pathways. In contrast, fibroblast cells tolerated expression of the same fusion oncogene without adverse effects, suggesting that some cell types are "permissive" while others are "non-permissive" to fusion oncogene expression. The central hypothesis of this project is that induction of autophagy-dependent cell death through innate immune signaling represents a conserved defense mechanism against fusion oncogene expression in non-permissive cell types. Specific Aims Aim 1: Determine the role of IL-6 signaling and differential fusion-binding patterns in the selective induction of autophagy-dependent cell death in EWSR1::CREB1-expressing cells. Studies will evaluate autophagic activity, localization of autophagy regulators, cell death mechanisms, and genomic binding patterns using molecular and imaging approaches. Aim 2: Investigate whether autophagy is a conserved tumor-suppressive response to oncogenic stress by conducting multiplexed proliferation screens of fusion oncogenes and measuring autophagic flux, cell death, and cytokine secretion. This work will provide new insight into how cells respond to fusion oncogene-induced stress and may reveal novel tumor-suppressive mechanisms operative in rare cancers. The findings could identify new therapeutic opportunities for cancers driven by fusion oncogenes.

    Read more
  • Title graphic with the text “Chengzhi Yu,” “Fu Research Group,” and “Funding provided by Cancer Research Institute” on a blue background.

    Decoding the RHIM Signalosome in the ZBP1-RIPK3 Pathway for Antitumor Immunity

    Cancer cells often evade detection by the immune system, limiting the effectiveness of cancer immunotherapies. One important but incompletely understood immune pathway centers on the protein ZBP1, which functions as an intracellular alarm sensor. When activated, ZBP1 can trigger inflammatory signaling and a specialized form of programmed cell death called necroptosis. These responses can help expose tumors to immune surveillance and promote anti-tumor immunity. However, the molecular mechanisms that activate and regulate this pathway remain poorly understood. Chengzhi Yu's research seeks to determine how ZBP1 and its signaling partner RIPK3 assemble into larger signaling complexes known as RHIM signalosomes. Using structural biology, high-resolution imaging, and biochemical approaches, the project will define the molecular mechanisms that govern activation of the ZBP1-RIPK3 pathway and inflammatory cell death. The research will also investigate how viral proteins, including proteins encoded by herpesviruses, interfere with RHIM signalosome formation and suppress immune responses. Understanding these viral evasion strategies may provide important insight into how immune signaling pathways are naturally regulated. By revealing the molecular "assembly instructions" that control ZBP1 signaling, this work aims to identify new approaches for enhancing anti-tumor immunity, overcoming immune suppression, and improving responses to cancer immunotherapies such as immune checkpoint blockade.

    Read more
  • Title graphic with the text “William Cruz,” “Korostelev Research Group,” and “Funding provided by National Institutes of Health” on a blue background.

    Understanding the Activation Mechanism of the Nutrition Sensor GCN2

    The protein kinase GCN2 is a regulator of translation during amino acid starvation and plays a critical role in cellular proliferation. Dysregulated GCN2 activity contributes to severe human diseases, including pulmonary arterial hypertension and pulmonary veno-occlusive disease, as well as cardiac diseases. Despite decades of study, the mechanism by which human GCN2 is activated in cells and how its full-length structure supports this regulation remains elusive. Existing models propose activation through either uncharged tRNA accumulation or stalled ribosome, but prior biochemical studies relied largely on purified components, leaving out essential ribosome-associated factors such as GCN1/GCN20, which are necessary for a greater picture of activation. Moreover, no complete structure of human GCN2 has been determined, leaving key regulatory linker regions poorly understood. This fellowship project seeks to define the molecular mechanism of human GCN2 activation and elucidate how linker regions contribute to GCN2 regulation. Aim 1 will determine the structure of activated full-length GCN2 in nutritionally starved lysate using cryo-electron microscopy, enabling visualization of GCN2 in the context of ribosomes, tRNA, and endogenous accessory proteins. Aim 2 will evaluate the regulatory roles of GCN2 linker regions using a HEK293-based system expressing targeted mutants, assessing effects on kinase activation, ribosome binding, and dimerization through biochemical and cell-based assays. Together, these aims will produce the first structural model of activated full-length human GCN2 and define how linker regions modulate GCN2’s function, providing insight relevant to diseases driven by aberrant GCN2. The proposed research is integrated with a comprehensive training plan designed to develop the fellow into an independent structural biologist. The fellowship includes structured technical training in cryo-EM grid preparation, data collection, and advanced image processing; biochemical and cell-based assays; and rigorous design of structural biology and computational experiments. The plan will also significantly enhance the fellow’s research knowledge of lysate-based structural methods, kinase signaling assays, and computational reconstruction of macromolecules. Completion of this fellowship will yield mechanistic insights into GCN2 activation while providing broad and deep scientific training that positions the fellow for a successful research career focused on mechanisms of translational control.

    Read more
  • Title graphic with the text “Matthew Wong,” “Munro and Schiffer Research Groups,” and “Funding provided by National Institutes of Health” on a blue background.

    Conformational Dynamics in HIV-1 Gag during Viral Maturation

    Human immunodeficiency virus type 1 (HIV-1) remains a major global health challenge. While viral maturation has long been a promising target for inhibitor development, the emergence ofresistance to protease inhibitors continues to limit their effectiveness. As such, the Group-Specific Antigen (Gag) polyprotein presents an alternative avenue for therapeutic intervention, marked by the recent development of novel antiretrovirals such as bevirimat and lenacapavir, which target the immature Gag and mature capsid (CA). Gag encodes the core structural proteins that form the viral particle and undergoes cleavage by the viral protease during maturation. Among the domains in Gag, CA-SP1 cleavage is the key determinant for CA maturation, a process marked by CA undergoing drastic conformational changes. In Aim 1, I will elucidate how the stability of SP1 helices evolves during proteolysis. SP1 helices are arranged mostly in relatively stable six-helix bundles in the immature lattice but are bound to the protease extended and unfolded. It remains unclear how SP1 loses its secondary structure as it binds to the protease. I hypothesize that the initial cleavage of a single SP1 helix destabilizes the six-helix bundle, promoting the unfolding of neighboring helices and allowing for easier access to the protease. Using MD simulations, I will elucidate and compare the unfolding timescale and mechanisms of SP1 helices within fully intact and partially cleaved hexamers. I predict that SP1 helices in the cleaved hexamers will unfold more readily, whereas the intact hexamer will remain predominantly stable. These simulations will provide mechanistic insights into how SP1 proteolysis propagates structural changes through the hexamer and contributes to how the crucial last step of Gag proteolytic processing occurs. The expertise from the Schiffer lab provides me with the necessary training needed to perform robust structural modeling and molecular dynamics simulations. In Aim 2, I will investigate how SP1 cleavage mediates CA conformational changes that facilitate maturation. The destabilization ofthe six-helix bundle has been identified as the key structural switch for CA maturation. Using smFRET, I will visualize the conformational changes of single CA molecules within oligomeric assemblies. I predict that destabilization of the six-helix bundle following CA-SP1 cleavage induces conformational changes to the CA domain that are relevant for virion maturation. These findings will provide mechanistic insights into the allosteric communication between the CA-SP1 cleavage site and CA domains, revealing how initial cleavage events prime the hexamer for further structural transitions. The Munro lab has a proven track record and expertise in visualizing dynamic events in virions using single molecule fluorescence- based techniques. This study will significantly advance our understanding of the molecular mechanisms underlying HIV-1 maturation, potentially shedding light on the maturation processes of other retroviruses.

    Read more
  • Person standing indoors near a staircase and glass railing, next to text identifying Rebecca Panwala of the Sontheimer and Xue Research Group, with funding provided by the National Institutes of Health.

    High throughput screening to generate and investigate cancer driver mutations in hepatocellular carcinoma.

    Cancer remains a leading cause of death in the United States and globally. Understanding the genetic mutations that drive cancer can help inform diagnosis, prognosis, and treatment options. Cancer driver mutations are thought to cause tumor formation and malignancy by leading to abnormal and uncontrolled cellular growth. To date, thousands of cancer driver mutations have been identified in hundreds of genes. Experimental models that precisely install cancer driver mutations are essential for investigating the mechanisms that underlie cancer. CRISPR-based prime editing offers a comprehensive way to generate a diverse array of cancer driver mutations, including substitutions, insertions, deletions, or combinations. In prime editing, a prime editing guide RNA (pegRNA) guides mutant Cas9 to nick one strand of the genome target site and serves as a template for reverse transcriptase (fused to Cas9) to copy new information into the genome. However, designing and validating effective pegRNAs is expensive and time-consuming. Preliminary experiments using a high-throughput screening approach based on Next Generation Sequencing identified pegRNAs that guide efficient editing. This screen enabled simultaneous testing of thousands of pegRNA designs for their ability to edit frequent mutations in hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer. This project aims to use these pegRNA constructs to further characterize HCC mutations and to generate a mouse model of HCC. Aim 1will characterize the cellular and molecular effects of HCC driver mutations. Utilizing a library of the highest efficacy pegRNAs from the preliminary screen, a secondary screen will be performed to identify which mutations confer a growth advantage in transformed primary human hepatocytes. Cellular fitness results from this screen will be validated using a competition assay. Cellular and molecular phenotypes of mutations that promote fitness will then be characterized. Colony formation assays will determine the ability of cells with cancer driver mutations to expand into a clonal population. RNA sequencing will reveal transcriptional profiles associated with the cancer mutation. Aim 2will model HCC driver mutations in vivo. Prime editing will be used to install cancer mutations in transformed primary human hepatocytes, and cells will be orthotopically implanted into the livers of immune-deficient mice via intrahepatic injection. After a period of growth, tumor formation and the histopathology and gene expression signatures of the tumors will be analyzed. This study will be piloted with pegRNAs (identified from the preliminary screen)that generated an activating mutation in the conserved -catenin gene CTNNB1.An activating mutation inCTNNB1combined with co-expression of the MYC oncogene was sufficient to drive tumor progression in mice. In vivo models of cancer driver mutations will be used to assess how tumors respond to treatment with first-line therapies for HCC. If successful, this project will generate a system to further characterize HCC driver mutations at the cellular level and in tumors, informing potential treatment approaches based on the genetic profiles of cancer.

    Read more
  • Person standing in front of a staircase, next to text identifying Emily Norman of the Francis Research Group, with funding provided by the National Institutes of Health.

    Cognitive decline is a major hallmark of aging

    Cognitive decline is a major hallmark of aging. Synapse loss and structural alterations are believed to be major contributing factors to normal age-related cognitive decline and are exacerbated in cases of neurodegenerative diseases such as Alzheimer's disease. The goal of this project is to identify conserved mechanisms responsible for synapse maintenance in aging animals. The short lifespan, invariant neuronal circuitry, and genetic tools available in the invertebrate Caenorhabditis elegans offer strong advantages for studies of synapse maintenance. While prior studies have largely focused on gross neuron morphological changes during aging, my work is focused on understanding age-related synapse changes. The Francis lab previously demonstrated that C. elegans GABAergic DD motor neurons have dendritic spines which share many characteristics with mammalian dendritic spines. My work focuses on understanding the mechanisms which regulate age-related synapse decline. My preliminary studies suggest that dendritic spine number is reduced in aging animals. My proposed work will define how aging impacts synapse structure and define the mechanisms required for synapse maintenance during aging (Aim 1). In Aim 2, I will identify potential postsynaptic targets crucial for synapse maintenance using proximity labeling and subsequent proteomic analyses. My proposed work will advance our understanding of the mechanisms regulating synapse maintenance in aging animals and potentially identify new gene targets for therapeutic intervention. Importantly, the proposed studies will also provide significant opportunities for new technical and professional training for the applicant.

    Read more
Showing 1-10 of 100 items
of 10